Market capitalization | $566.36m |
Enterprise Value | $510.78m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 1.72 |
P/S ratio (TTM) P/S ratio | 1.91 |
P/B ratio (TTM) P/B ratio | 2.50 |
Revenue growth (TTM) Revenue growth | 20.69% |
Revenue (TTM) Revenue | $296.59m |
As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.
6 Analysts have issued a Pharming Group N.V. - ADR forecast:
6 Analysts have issued a Pharming Group N.V. - ADR forecast:
Dec '24 |
+/-
%
|
||
Revenue | 297 297 |
21%
21%
|
|
Gross Profit | 270 270 |
27%
27%
|
|
EBITDA | 5.32 5.32 |
142%
142%
|
EBIT (Operating Income) EBIT | -11 -11 |
63%
63%
|
Net Profit | -11 -11 |
7%
7%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Pharming Group NV is a holding company, which engages in the development of pharmaceutical products for the treatment of rare diseases and unmet medical needs. The company offers RUCONEST which is a recombinant human C1-esterase inhibitor for the treatment of acute hereditary angioedema. It operates through the following geographical segments: the United States, Europe, and Rest of the World. The company was founded on November 11, 1988 and is headquartered in Leiden, the Netherlands.
Head office | Netherlands |
CEO | Fabrice Chouraqui |
Founded | 1988 |
Website | www.pharming.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.